Skip to main content

Advertisement

SpringerLink
Log in

The Renin–Angiotensin System and Bone

  • Hypertension and bone
  • Published:
Clinical Reviews in Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

The RAS (renin–angiotensin system) plays a key role in the regulation of blood pressure, fluid and electrolyte homeostasis and cardiovascular and renal structure and function. There is evidence that in addition to the systemic RAS the components of the RAS are expressed in the local milieu of bone, where angiotensin II increases the osteoclastogenesis while inhibit the osteoblastic activity leading to a decrease in bone mineral density. Hypertension and osteoporosis are two common diseases that frequently coexist in the elderly population, and it has been hypothesized that the activation of the local RAS might be involved in the occurrence of both diseases often seen with advancing age. Epidemiological studies have found that RAS inhibitors, including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, may exert a beneficial effect on bone mineral density, increasing the bone mass and decreasing the risk of bone fractures in patients with osteoporosis and cardiovascular diseases, and might accelerate the fracture healing process. However, both experimental and clinical studies with these RAS inhibitors led to sparse and contradictory results. Thus, in the next future a better understanding on how the components of the local RAS influence bone metabolism and remodeling will allow us to select the best therapeutic strategy for patients with osteoporosis and cardiovascular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.

    Article  PubMed  Google Scholar 

  2. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2012;33(13):1635–701.

    Article  CAS  PubMed  Google Scholar 

  3. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026–33.

    Article  CAS  PubMed  Google Scholar 

  4. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Farag E, Maheshwari K, Morgan J, Esa WAS, Doyle DJ. An update of the role of renin angiotensin in cardiovascular homeostasis. Anesth Analg. 2015;120(2):275–92.

    Article  CAS  PubMed  Google Scholar 

  6. Dendorfer A, Dominiak P, Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol. 2005;170:407–42.

    Article  CAS  PubMed  Google Scholar 

  7. Tamargo J, Duarte J, Ruilope LM. New antihypertensive drugs under development. Curr Med Chem. 2015;22(3):305–42.

    Article  CAS  PubMed  Google Scholar 

  8. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Leung PS, Sernia C. The renin-angiotensin system and male reproduction: new functions for old hormones. Mol Cell Endocrinol. 2003;30(3):263–70.

    Article  CAS  Google Scholar 

  10. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012;302(6):H1219–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Gironacci MM, Cerniello FM, Carbajosa NAL, Goldstein J, Cerrato BD. Protective axis of the renin-angiotensin system in the brain. Clin Sci. 2014;127(5):295–306 (Lond).

    Article  CAS  PubMed  Google Scholar 

  12. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52(3):415–72.

    PubMed  Google Scholar 

  13. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504–8.

    Article  CAS  PubMed  Google Scholar 

  14. Rodan GA, Martin TJ. Therapeutic approaches to bone disease. Science. 2000;289(5484):1508–14.

    Article  CAS  PubMed  Google Scholar 

  15. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA. 1990;87(18):7260–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170(2):427–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005;202(9):1261–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab. 2012;23(11):582–90.

    Article  CAS  PubMed  Google Scholar 

  20. Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res. 2013;28(4):711–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Walsh CW, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone and beyond. Frontiers Inmmunol. 2014;5(5):1–8.

    CAS  Google Scholar 

  22. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.

    Article  CAS  PubMed  Google Scholar 

  23. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95(7):3597–602.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun. 2005;328(3):688–96.

    Article  CAS  PubMed  Google Scholar 

  25. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12(1):17–25.

    Article  CAS  PubMed  Google Scholar 

  26. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol. 2006;3(1):41–9.

    Article  CAS  PubMed  Google Scholar 

  27. Lee S-K, Lorenzo J. Cyrokine regulating osteoclast formation and function. Curr Opin Rheumatol. 2006;18(4):411–8.

    Article  CAS  PubMed  Google Scholar 

  28. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–23.

    Article  CAS  PubMed  Google Scholar 

  29. Kikuta J, Ishii M. Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology. 2013;52(2):226–34 (Oxford).

    Article  CAS  PubMed  Google Scholar 

  30. Tat SK, Padrines M, Theoleyre S, Couillaud-Battaglia S, Heymann D, Redini F, Fortun Y. OPG/membranous—RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone. 2006;39(4):706–15.

    Article  CAS  PubMed  Google Scholar 

  31. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int. 2005;16(4):417–23.

    Article  CAS  PubMed  Google Scholar 

  33. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15(6):457–75.

    Article  CAS  PubMed  Google Scholar 

  34. Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol. 2011;7(11):631–8.

    Article  CAS  PubMed  Google Scholar 

  35. Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, et al. Segregation of TRAF6-mediated signalling pathways clarifies its role in osteoclastogenesis. EMBO J. 2001;20(6):1271–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. CGTP Collaborators. the concise guide to pharmacology 2013/14: G protein-coupled receptors. Br J Pharmacol. 2013;170(8):1459–581.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem. 1993;268(33):24539–42.

    CAS  PubMed  Google Scholar 

  38. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Beinstein KE. Isolation of a cDNA encoding the vascular type 1 angiotensin II receptor. Nature. 1991;351(6323):233–6.

    Article  CAS  PubMed  Google Scholar 

  39. Haendeler J, Berk BC. Angiotensin II mediated signal transduction. Important role of tyrosine kinases. Regul Pept. 2000;95(1–3):1–7.

    Article  CAS  PubMed  Google Scholar 

  40. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci. 2007;112(8):417–28 (Lond).

    Article  CAS  PubMed  Google Scholar 

  41. Paul M, Poyan Mehr A, Kreuz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747–803.

    Article  CAS  PubMed  Google Scholar 

  42. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab. 2000;11(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  43. Lemarié CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2010;11(1):19–31.

    Article  PubMed  Google Scholar 

  44. Steckelings UM, Rompe F, Kaschina E, Namsolleck P, Grzesiak A, Funke-Kaiser H, et al. The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angiotensin Aldosterone Syst. 2010;11(1):67–73.

    Article  CAS  PubMed  Google Scholar 

  45. Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens. 2005;18(9 Pt 2):134S–41S.

    Article  CAS  PubMed  Google Scholar 

  46. Pessôa BS, van der Lubbe N, Verdonk K, Roks AJ, Hoorn EJ, Danser AJ. Key developments in renin–angiotensin—aldosterone system inhibition. Nat Rev Nephrol. 2013;9(1):26–36.

    Article  CAS  Google Scholar 

  47. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33(2):613–21.

    Article  CAS  PubMed  Google Scholar 

  48. Akishita M, Yamada H, Dzau VJ, Horiuchi M. Increased vasoconstrictor response of the mouse lacking angiotensin II type 2 receptor. Biochem Biophys Res Commun. 1999;261(2):345–9.

    Article  CAS  PubMed  Google Scholar 

  49. Abdalla S, Lother H, Abdel-tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem. 2001;276(43):39721–6.

    Article  CAS  PubMed  Google Scholar 

  50. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol. 2013;216(2):R1–17.

    Article  CAS  PubMed  Google Scholar 

  51. Speth RC, Giese MJ. Update on the renin-angiotensin system. J Pharmacol Clin Toxicol. 2013;1(1):1–13.

    Google Scholar 

  52. Carey RM. Newly discovered components and actions of the renin-angiotensin system. Hypertension. 2013;62(5):818–22.

    Article  CAS  PubMed  Google Scholar 

  53. Santos RA, e Silva ACS, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100(14):8258–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275(43):33238–43.

    Article  CAS  PubMed  Google Scholar 

  55. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, et al. Therapeutic implications of the vasoprotective axis of the renin–angiotensin system in cardiovascular diseases. Hypertension. 2010;55(2):207–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109(11):1417–27.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Funke-Kaiser H, Zollmann FS, Schefe JH, Unger T. Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res. 2010;33(2):98–104.

    Article  CAS  PubMed  Google Scholar 

  58. Krop M, Lu X, Danser AH, Meima ME. The (pro)renin receptor. a decade of research: what have we learned? Pflugers Arch. 2013;465(1):87–97.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol. 2010;105(1 Suppl):30A–5A.

    Article  CAS  PubMed  Google Scholar 

  60. Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, et al. Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem. 2009;284(8):4857–64.

    Article  CAS  PubMed  Google Scholar 

  61. Kaneko K, Ito M, Fumoto T, Fukuhara R, Ishida J, Fukamizu A, et al. Physiological function of the angiotensin AT1a receptor in bone remodeling. J Bone Miner Res. 2011;26(12):2959–66.

    Article  CAS  PubMed  Google Scholar 

  62. Bandow K, Nishikawa Y, Ohnishi T, Kakimoto K, Soejima K, Iwabuchi S, et al. Low-intensity pulsed ultrasound (LIPUS) induces RANKL, MCP-1, and MIP-1beta expression in osteoblasts through the angiotensin II type 1 receptor. J Cell Physiol. 2007;211(2):392–8.

    Article  CAS  PubMed  Google Scholar 

  63. Hatton R, Stimpel M, Chambers TJ. Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol. 1997;152(1):5–10.

    Article  CAS  PubMed  Google Scholar 

  64. Sernia C, Li L, Huang H, Nguyuen K, Li YH, Hsu S, et al. Bone homeostasis: an emerging role for the renin-angiotensin system. In: Leung PS, editor. Frontiers in research of the renin-angiotensin system on human disease. New York: Springer; 2007. p. 179–95.

    Google Scholar 

  65. Gu SS, Zhang Y, Li XL, Wu SY, Diao TY, Hai R, et al. Involvement of the skeletal renin-angiotensin system in age-related osteoporosis of ageing mice. Biosci Biotechnol Biochem. 2012;76(7):1367–71.

    Article  CAS  PubMed  Google Scholar 

  66. Shuai B, Yang YP, Shen L, Zhu R, Xu XJ, Ma C, et al. Local renin-angiotensin system is associated with bone mineral density of glucocorticoid-induced osteoporosis patients. Osteoporos Int. 2015;26(3):1063–71.

    Article  CAS  PubMed  Google Scholar 

  67. Yongtao Z, Kunzheng W, Jingjing Z, Hu S, Jianqiang K, Ruiyu L, Chunsheng W. Glucocorticoids activate the local renin-angiotensin system in bone: possible mechanism for glucocorticoid-induced osteoporosis. Endocrine. 2014;47(2):598–608.

    Article  PubMed  CAS  Google Scholar 

  68. Zhang Y, Diao TY, Gu SS, Wu SY, Gebru YA, Chen X, et al. Effects of angiotensin II type 1 receptor blocker on bones in mice with type 1 diabetes induced by streptozotocin. J Renin Angiotensin Aldosterone Syst. 2014;15(3):218–27.

    Article  CAS  PubMed  Google Scholar 

  69. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res. 2009;24(2):241–50.

    Article  CAS  PubMed  Google Scholar 

  70. Hagiwara H, Hiruma Y, Inoue A, Yamaguchi A, Hirose S. Deceleration by angiotensin II of the differentiation and bone formation of rat calvarial osteoblastic cells. J Endocrinol. 1998;156(3):543–50.

    Article  CAS  PubMed  Google Scholar 

  71. Lamparter S, Kling L, Schrader M, Ziegler R, Pfeilschifter J. Effects of angiotensin II on bone cells in vitro. J Cell Physiol. 1998;175(1):89–98.

    Article  CAS  PubMed  Google Scholar 

  72. Bowler WB, Gallagher JA, Bilbe G. G-protein coupled receptors in bone. Front Biosci. 1998;1:d769–80.

    Google Scholar 

  73. Tsukamoto I, Akagi M, Inoue S, Yamagishi K, Mori S, Asada S. Expressions of local renin-angiotensin system components in chondrocytes. Eur J Histochem. 2014;58(2):2387.

    PubMed Central  CAS  PubMed  Google Scholar 

  74. Haznedaroglu IC, Beyazit Y. Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. J Renin Angiotensin Aldosterone Syst. 2010;11(4):205–13.

    Article  CAS  PubMed  Google Scholar 

  75. Strawn WB, Richmond RS, Ann Tallant E, Gallagher PE, Ferrario CM. Renin–angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol. 2004;126(1):120–6.

    Article  CAS  PubMed  Google Scholar 

  76. Haznedaroglu IC, Beyazit Y. Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis. Clin Sci. 2013;124(5):307–23 (Lond).

    Article  CAS  PubMed  Google Scholar 

  77. Beyazit Y, Purnak T, Guven GS, Haznedaroglu IC. Local bone marrow renin-angiotensin system and atherosclerosis. Cardiol Res Pract. 2011;1(1):714515.

    Google Scholar 

  78. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100(9):2310–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18(4):287–94.

    Article  CAS  PubMed  Google Scholar 

  80. Savary K, Michaud A, Favier J, Larger E, Corvol P, Gasc JM. Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo. Blood. 2005;105(1):103–10.

    Article  CAS  PubMed  Google Scholar 

  81. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008;22(7):2465–75.

    Article  CAS  PubMed  Google Scholar 

  82. Shimizu H, Nakagami H, Osako MK, Nakagami F, Kunugiza Y, Tomita T, et al. Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens Res. 2009;32(9):786–90.

    Article  CAS  PubMed  Google Scholar 

  83. Hiruma Y, Inoue A, Hirose S, Hagiwara H. Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun. 1997;230(1):176–8.

    Article  CAS  PubMed  Google Scholar 

  84. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem. 1995;270(32):18719–22.

    Article  CAS  PubMed  Google Scholar 

  85. Nakagami H, Morishita R. Hormones and osteoporosis update. Effect of angiotensin II on bone metabolism. Clin Calcium. 2009;19(7):997–1002.

    CAS  PubMed  Google Scholar 

  86. Dossing DA, Stern PH. Receptor activator of NF-kappa B ligand protein expression in UMR-106 cells is differentially regulated by parathyroid hormone and calcitriol. J Cell Biochem. 2005;95(5):1029–41.

    Article  CAS  PubMed  Google Scholar 

  87. Osako MK, Nakagami H, Shimamura M, Koriyama H, Nakagami F, Shimizu H, et al. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification. Arterioscler Thromb Vasc Biol. 2013;33(6):1287–96.

    Article  CAS  PubMed  Google Scholar 

  88. Guan XX, Zhou Y, Li JY. Reciprocal roles of angiotensin II and Angiotensin II Receptors Blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis. Int J Mol Sci. 2011;12(7):4206–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  89. Tintut Y, Parhami F, Le V, Karsenty G, Demer LL. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. J Biol Chem. 1999;274(41):28875–9.

    Article  CAS  PubMed  Google Scholar 

  90. Thaler R, Spitzer S, Rumpler M, Fratzl-Zelman N, Klaushofer K, Paschalis EP, et al. Differential effects of homocysteine and beta aminopropionitrile on preosteoblastic MC3T3-E1 cells. Bone. 2010;46(3):703–9.

    Article  CAS  PubMed  Google Scholar 

  91. Cola C, Almeida M, Li D, Romeo F, Mehta JL. Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem Biophys Res Commun. 2004;320(2):424–7.

    Article  CAS  PubMed  Google Scholar 

  92. Kubalak SW, Webb JG. Angiotensin II enhancement of hormone-stimulated cAMP formation in cultured vascular smooth muscle cells. Am J Physiol. 1993;264(1 Pt 2):H86–96.

    CAS  PubMed  Google Scholar 

  93. MacGregor GA, Cappuccio FP. The kidney and essential hypertension: a link to osteoporosis? J Hypertens. 1993;11(8):781–5.

    Article  CAS  PubMed  Google Scholar 

  94. Neelon FA, Birch BM, Drezner M, Lebovitz HE. Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism. Lancet. 1973;1(7804):631–3.

    Article  CAS  PubMed  Google Scholar 

  95. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res. 2010;25(9):1897–904.

    Article  CAS  PubMed  Google Scholar 

  96. Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751–64.

    Article  CAS  PubMed  Google Scholar 

  97. Bai S, Kopan R, Zou W, Hilton MJ, Ong CT, Long F, et al. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem. 2008;283(10):6509–18.

    Article  CAS  PubMed  Google Scholar 

  98. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860–9.

    Article  PubMed  Google Scholar 

  99. Nakai K, Kawato T, Morita T, Iinuma T, Kamio N, Zhao N, et al. Angiotensin II induces the production of MMP-3 and MMP-13 through the MAPK signaling pathways via the AT(1) receptor in osteoblasts. Biochimie. 2013;95(4):922–33.

    Article  CAS  PubMed  Google Scholar 

  100. Guo L, Wang M, Zhang ZY, Hao L, Lou BY, Li XY, et al. Angiotensin II induces interleukin-6 synthesis in osteoblasts through ERK1/2 pathway via AT1 receptor. Arch Oral Biol. 2011;56(3):205–11.

    Article  CAS  PubMed  Google Scholar 

  101. Algan SM, Purdon M, Horowitz SM. Role of tumor necrosis factor alpha in particulate-induced bone resorption. J Orthop Res. 1996;14(1):30–5.

    Article  CAS  PubMed  Google Scholar 

  102. Seck T, Diel I, Bismar H, Ziegler R, Pfeilschifter J. Expression of interleukin-6 (IL-6) and IL-6 receptor mRNA in human bone samples from pre- and postmenopausal women. Bone. 2002;30(1):217–22.

    Article  CAS  PubMed  Google Scholar 

  103. Dai JC, He P, Chen X, Greenfield EM. TNF alpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone. 2006;38(4):509–20.

    Article  CAS  PubMed  Google Scholar 

  104. Patil C, Zhu X, Rossa C Jr, Kim YJ, Kirkwood KL. p38 MAPK regulates IL-1 beta induced IL-6 expression through mRNA stability in osteoblasts. Immunol Invest. 2004;33(2):213–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  105. Niida S, Kondo T, Hiratsuka S, Hayashi S, Amizuka N, Noda T, et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci USA. 2005;102(39):14016–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  106. Li G, Wang M, Hao L, Loo WT, Jin L, Cheung MN, et al. Angiotensin II induces mitochondrial dysfunction and promotes apoptosis via JNK signalling pathway in primary mouse calvaria osteoblast. Arch Oral Biol. 2014;59(5):513–23.

    Article  CAS  PubMed  Google Scholar 

  107. Schurman SJ, Bergstrom WH, Shoemaker LR, Welch TR. Angiotensin II reduces calcium uptake into bone. Pediatr Nephrol. 2004;19(1):33–5.

    Article  PubMed  Google Scholar 

  108. Grant FD, Mandel SJ, Brown EM, Williams GH, Seely EW. Interrelationships between the renin-angiotensin-aldosterone and calcium homeostatic systems. J Clin Endocrinol Metab. 1992;75(4):988–92.

    CAS  PubMed  Google Scholar 

  109. Kanaan RA, Kanaan LA. Transforming growth factor beta1, bone connection. Med Sci Monit. 2006;12(8):164–9.

    Google Scholar 

  110. Fox SW, Lovibond AC. Current insights into the role of transforming growth factor-β in bone resorption. Molec Cell Endocrinol. 2005;243(1–2):19–26.

    Article  CAS  PubMed  Google Scholar 

  111. Brown RE. Angiotensin-converting enzyme, transforming growth factor beta(1), and interleukin 11 in the osteolytic lesions of Langerhans cell Histiocytosis. Arch Pathol Lab Med. 2000;124(9):1287–90.

    CAS  PubMed  Google Scholar 

  112. Alagiakrishnan K, Juby A, Hanley D, Tymchak W, Sclater A. Role of vascular factors in osteoporosis. J Gerontol. 2003;58(4):362–6.

    Article  Google Scholar 

  113. Rajkumar DS, Faitelson AV, Gudyrev OS, Dubrovin GM, Pokrovski MV, Ivanov AV. Comparative evaluation of enalapril and losartan in pharmacological correction of experimental osteoporosis and fractures of its background. J Osteoporos. 2013;2013:325693.

    PubMed Central  CAS  PubMed  Google Scholar 

  114. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007;21(1):109–22.

    Article  PubMed  Google Scholar 

  115. NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–95.

    Article  Google Scholar 

  116. Flieger J, Karachalios T, Khaldi L, Raptou P, Lyritis G. Mechanical stimulation in the form of vibration prevents postmenopausal bone loss in ovariectomized rats. Calcif Tissue Int. 1998;63(6):510–4.

    Article  CAS  PubMed  Google Scholar 

  117. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106(3):273–8.

    Article  PubMed  Google Scholar 

  118. Choi SH, An JH, Lim S, Koo BK, Park SE, Chang HJ, et al. Lower bone mineral density is associated with higher coronary calcification and coronary plaque burdens by multidetector row coronary computed tomography in pre- and postmenopausal women. Clin Endocrinol. 2009;71(5):644–51 (Oxf).

    Article  Google Scholar 

  119. Nishio K, Mukae S, Aoki S, Itoh S, Konno N, Ozawa K, et al. Congestive heart failure is associated with the rate of bone loss. J Intern Med. 2003;253(4):439–46.

    Article  CAS  PubMed  Google Scholar 

  120. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women, men: the Framingham Heart Study. JAMA. 2002;287(8):1003–10.

    Article  PubMed  Google Scholar 

  121. Resnick LM, Laragh JH, Sealey JE, Alderman MH. Divalent cations in essential hypertension: relations between serum ionized calcium, magnesium, and plasma renin activity. N Engl J Med. 1983;309(15):888–91.

    Article  CAS  PubMed  Google Scholar 

  122. Strazzullo P, Nunziata V, Cirillo M, Giannattasio R, Ferrara LA, Mattioli PL, et al. Abnormalities of calcium metabolism in essential hypertension. Clin Sci. 1983;65(2):137–41 (Lond).

    Article  CAS  PubMed  Google Scholar 

  123. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet. 1999;354(9183):971–5.

    Article  CAS  PubMed  Google Scholar 

  124. McCarron DA, Pingree PA, Rubin RJ, Gaucher SM, Molitch M, Krutzik S. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension. 1980;2(2):162–8.

    Article  CAS  PubMed  Google Scholar 

  125. McCarron DA. Low serum concentrations of ionized calcium in patients with hypertension. N Engl J Med. 1982;307(4):226–8.

    Article  CAS  PubMed  Google Scholar 

  126. Ilic K, Obradovic N, Vujasinovic-Stupar N. The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int. 2013;92(3):217–27.

    Article  CAS  PubMed  Google Scholar 

  127. Tsuda K, Nishio I, Masuyama Y. Bone Mineral Density in Women With Essential Hypertension. Am J Hypertens. 2001;14(7 Pt 1):704–7.

    Article  CAS  PubMed  Google Scholar 

  128. Lynn H, Kwok T, Wong SY, Woo J, Leung PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone. 2006;38(4):584–8.

    Article  CAS  PubMed  Google Scholar 

  129. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens. 2006;24(3):581–9.

    Article  CAS  PubMed  Google Scholar 

  130. Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between hypertension and fragility fracture: a longitudinal study. Osteoporos Int. 2014;25(1):97–103.

    Article  CAS  PubMed  Google Scholar 

  131. Liu HW, Iwai M, Takeda-Matsubara Y, Wu L, Li JM, Okumura M, et al. Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension. 2002;40(4):451–7.

    Article  PubMed  Google Scholar 

  132. Zhang Y, Wang K, Song Q, Liu R, Ji W, Ji L, et al. Role of the local bone renin-angiotensin system in steroid-induced osteonecrosis in rabbits. Mol Med Rep. 2014;9(4):1128–34.

    CAS  PubMed  Google Scholar 

  133. Garcia P, Schwenzer S, Slotta JE, Scheuer C, Tami AE, Holstein JH, et al. Inhibition of angiotensin-converting enzyme stimulates fracture healing and periosteal callus formation-role of a local renin-angiotensin system. Br J Pharmacol. 2010;159(8):1672–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  134. Gu SS, Zhang Y, Wu SY, Diao TY, Gebru YA, Deng H. Early molecular responses of bone to obstructive nephropathy induced by unilateral ureteral obstruction in mice. Nephrology. 2012;17(8):767–73.

    Article  CAS  PubMed  Google Scholar 

  135. Diao TY, Pan H, Gu SS, Chen X, Zhang FY, Wong MS, et al. Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes. J Bone Miner Metab. 2014;32(3):261–70.

    Article  CAS  PubMed  Google Scholar 

  136. Donmez BO, Ozdemir S, Sarikanat M, Yaras N, Koc P, Demir N, et al. Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Rep. 2012;64(4):878–88.

    Article  CAS  PubMed  Google Scholar 

  137. Takeda-Matsubara Y, Nakagami H, Iwai M, Cui TX, Shiuchi T, Akishita M, et al. Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension. 2002;39(1):41–5.

    Article  CAS  PubMed  Google Scholar 

  138. Liu YY, Yao WM, Wu T, Xu BL, Chen F, Cui L. Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts. J Bone Miner Metab. 2011;29(2):149–58.

    Article  PubMed  CAS  Google Scholar 

  139. Pérez-Castrillón JL, Justo I, Silva J, Sanz A, Martín-Escudero JC, Igea R, et al. Relationship between bone mineral density and angiotensin converting enzyme polymorphism in hypertensive postmenopausal women. Am J Hypertens. 2003;16(3):233–5.

    Article  PubMed  Google Scholar 

  140. Woods D, Onambele G, Woledge R, Skelton D, Bruce S, Humphries SE, et al. Angiotensin-I converting enzyme genotype-dependent benefit from hormone replacement therapy in isometric muscle strength and bone mineral density. J Clin Endocrinol Metab. 2001;86(5):2200–4.

    CAS  PubMed  Google Scholar 

  141. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15(4):323–8.

    Article  CAS  PubMed  Google Scholar 

  142. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224–9.

    Article  PubMed  CAS  Google Scholar 

  143. Skov J, Persson F, Frøkiær J, Christiansen JS. Tissue renin-angiotensin systems: a unifying hypothesis of metabolic disease. Front Endocrinol. 2014;5:23 (Lausanne).

    Article  Google Scholar 

  144. Pérez-Castrillón JL, Silva J, Justo I, Sanz A, Martín-Luquero M, Igea R, et al. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens. 2003;16(6):453–9.

    Article  PubMed  CAS  Google Scholar 

  145. Kang KY, Kang Y, Kim M, Kim Y, Yi H, Kim J, et al. The effects of antihypertensive drugs on bone mineral density in ovariectomized mice. J Korean Med Sci. 2013;28(8):1139–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  146. Broulík PD, Tesar V, Zima T, Jirsa M. Impact of antihypertensive therapy on the skeleton: effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiol Res. 2001;50(4):353–8.

    PubMed  Google Scholar 

  147. Stimpel M, Jee WS, Ma Y, Yamamoto N, Chen Y. Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats. J Hypertens. 1995;13(12 Pt 2):1852–6.

    CAS  PubMed  Google Scholar 

  148. Ma YF, Stimpel M, Liang H, Pun S, Jee WS. Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol. 1997;154(3):467–74.

    Article  CAS  PubMed  Google Scholar 

  149. García-Testal A, Monzó A, Rabanaque G, González A, Romeu A. Evolution of the bone mass of hypertense menopausal women in treatment with fosinopril. Med Clin. 2006;127(18):692–4 (Barc).

    Article  Google Scholar 

  150. Nakagami H, Kiomy O, Shimizu H, Hanayama R, Morishita R. Potential contribution of action of renin angiotensin system to bone metabolism. Curr Hypertens Rev. 2007;3(2):129–32.

    Article  CAS  Google Scholar 

  151. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA. 2004;292(11):1326–32.

    Article  CAS  PubMed  Google Scholar 

  152. Solomon DH, Mogun H, Garneau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res. 2011;26(7):1561–7.

    Article  CAS  PubMed  Google Scholar 

  153. Kwok T, Leung J, Zhang YF, Bauer D, Ensrud KE, Barrett-Connor E, et al. Osteoporotic Fractures inMen(MrOS) Research Group. Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporos Int. 2012;23(8):2159–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  154. Masunari N, Fujiwara S, Nakata Y, Furukawa K, Kasagi F. Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese. Hiroshima J Med Sci. 2008;57(1):17–25.

    PubMed  Google Scholar 

  155. Zhang YF, Qin L, Leung PC, Kwok TC. The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese. J Bone Miner Metab. 2012;30(6):666–73.

    Article  CAS  PubMed  Google Scholar 

  156. Daikuhara H, Fukunaga K, Ohshima T. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study. Drug Des Devel Ther. 2014;8:219–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  157. Ma L, Ji JL, Ji H, Yu X, Ding LJ, Liu K, et al. Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats. Bone. 2010;47(1):5–11.

    Article  CAS  PubMed  Google Scholar 

  158. Zhao X, Wang JX, Feng YF, Wu ZX, Zhang Y, Shi L, et al. Systemic treatment with telmisartan improves femur fracture healing in mice. PLoS One. 2014;9(3):e92085.

    Article  PubMed Central  PubMed  Google Scholar 

  159. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113(6):846–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  160. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 2007;13(12):1496–503.

    Article  CAS  PubMed  Google Scholar 

  161. Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B. PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem. 2009;106(2):232–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  162. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148(6):2669–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  163. Lecka-Czernik B. Bone loss in diabetes: use of anti-diabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8(4):178–84.

    Article  PubMed Central  PubMed  Google Scholar 

  164. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation. 2004;109(17):2054–7.

    Article  CAS  PubMed  Google Scholar 

  165. Kolli V, Stechschulte LA, Dowling AR, Rahman S, Czernik PJ, Lecka-Czernik B. Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass. PLoS One. 2014;9(5):e96323.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  166. Li YQ, Ji H, Shen Y, Ding LJ, Zhuang P, Yang YL, et al. Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats. Can J Physiol Pharmacol. 2009;87(1):51–5.

    Article  CAS  PubMed  Google Scholar 

  167. Zhang YF, Qin L, Kwok TC, Yeung BH, Li GD, Liu F. Effect of angiotensin II type I receptor blocker losartan on bone deterioration in orchiectomized male hypertensive and normotensive rats. Chin Med J. 2013;126(14):2661–5 (Engl).

    CAS  PubMed  Google Scholar 

  168. Butt DA, Mamdani M, Gomes T, Lix L, Lu H, Tu K. Tu K; Hypertension Outcome, Surveillance Team. Risk of osteoporotic fractures with angiotensin II receptor blockers versus angiotensin converting-enzyme inhibitors in hypertensive community-dwelling elderly. J Bone Miner Res. 2014;29(11):2483–8.

    Article  CAS  PubMed  Google Scholar 

  169. Nishiya Y, Sugimoto S. Effects of various antihypertensive drugs on the function of osteoblast. Biol Pharm Bull. 2001;24(6):628–33.

    Article  CAS  PubMed  Google Scholar 

  170. Zhu YC, Zhu YZ, Li J, Schäfer H, Schmidt WE, Unger T, et al. Effects of ramipril on cardiac gene transcription levels of angiotensin II receptors after myocardial infarction. Zhongguo yao lixue bao. 1999;20(6):481–5.

    CAS  Google Scholar 

  171. Bouscarel B, Wilson PB, Blackmore PF, Lynch CJ, Exton JH. Agonist-induced down-regulation of the angiotensin II receptor in primary cultures of rat hepatocytes. J Biol Chem. 1988;263(29):14920–4.

    CAS  PubMed  Google Scholar 

  172. Wilms H, Rosenstiel P, Unger T, Deuschl G, Lucius R. Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. Am J Cardiovasc Drugs. 2005;5(4):245–53.

    Article  CAS  PubMed  Google Scholar 

  173. Zhang Z, Zhang Y, Ning G, Kong J, Deb DK, Li YC. Combination therapy with AT1 receptor blocker and vitamin D analog markedly ameliorates diabetic nephropathy. Proc Natl Acad Sci U S A. 2008;105(41):15896–901.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  174. Danser AH. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? Hypertens Res. 2010;33(1):4–10.

    Article  CAS  PubMed  Google Scholar 

  175. Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vasc Health Risk Manag. 2009;5(1):453–63.

    PubMed Central  PubMed  Google Scholar 

  176. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92(4):825–34.

    Article  CAS  PubMed  Google Scholar 

  177. Kwok T, Ohlsson C, Vandenput L, Tang N, Zhang YF, Tomlinson B, et al. ACE inhibitor use was associated with lower serum dehydroepiandrosterone concentrations in older men. Clin Chim Acta. 2010;411(15–16):1122–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  178. Koshida H, Takeda R, Miyamori I. Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients. Hypertens Res. 1998;21(4):279–82.

    Article  CAS  PubMed  Google Scholar 

  179. Hoppé E, Bouvard B, Royer M, Audran M, Legrand E. Sex hormone-binding globulin in osteoporosis. Joint Bone Spine. 2010;77(4):306–12.

    Article  PubMed  CAS  Google Scholar 

  180. Schiling P, Löffler G. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensinogen system in human preadipocytes. Horm Metab Res. 2001;33(4):189–95.

    Article  Google Scholar 

  181. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, et al. Angiotensin 2 receptor blocker valsartan suppresses reactive oxygen species generation in leucocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J Clin Endocrinol Metab. 2003;88(9):4496–501.

    Article  CAS  PubMed  Google Scholar 

  182. Bergula A, Huang W, Frangos J. Femoral vein ligation increases bone mass in the hindlimb suspended rat. Bone. 1999;24(3):171–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

To Paloma Vaquero for her technical assistance.

Funding

This review was supported by Instituto de Salud Carlos III (Red RIC, and PI11/01030) and Comunidad de Madrid (S2010/BMD-2374).

Author information

Authors and Affiliations

  1. Department of Pharmacology, School of Medicine, Universidad Complutense, 28040, Madrid, Spain

    Juan Tamargo, Ricardo Caballero & Eva Delpón

Authors
  1. Juan Tamargo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ricardo Caballero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eva Delpón
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juan Tamargo.

Ethics declarations

Conflicts of interest

Juan Tamargo, Ricardo Caballero, and Eva Delpón declare that they do not have any conflict of interest.

Animal/Human studies

The article does not contain any studies with human or animal subjects performed by the any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tamargo, J., Caballero, R. & Delpón, E. The Renin–Angiotensin System and Bone. Clinic Rev Bone Miner Metab 13, 125–148 (2015). https://doi.org/10.1007/s12018-015-9189-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12018-015-9189-6

Keywords

Search

Navigation